Pfizer Plans $31 Billion Debt Offering for Seagen Acquisition Amid Revenue Challenges

Published by MEXEM Technical Analysis

July 25, 2024 2:51 PM

(GMT+2)

Published - May 17th, 2023 @ 10:30 AM (GMT+2)

‍

Pfizer seeks to raise $31 billion for Seagen acquisition

‍

Pfizer Inc announced on Tuesday its intention to raise $31 billion through a debt offering, aimed at funding the proposed acquisition of Seagen Inc. In March, the pharmaceutical giant entered into a $43 billion agreement to acquire Seagen, a move to bolster its targeted cancer therapy offerings as it faces diminishing {{mtag option="search" tag="COVID-19"}} sales and increased competition from generic drugs.
‍

‍
Company invests billions to counter $17 billion revenue shortfall by 2030

‍

To counter an expected $17 billion revenue shortfall by 2030 due to patent expirations and dwindling demand for COVID-related products, Pfizer has invested heavily in research and strategic acquisitions. The Seagen acquisition serves as a significant part of this strategy.

The proposed debt offering is scheduled to close on May 19, with the funds being divided into eight tranches. BofA Securities, Citigroup, Goldman Sachs, and J.P. Morgan have been appointed as joint lead managers and joint book-running managers for the transaction.

The information on mexem.com is for general informational purposes only. It should not be regarded as investment advice. Investing in stocks involves risk. A stock's past performance is not a reliable indicator of its future performance. Always consult a financial advisor or trusted sources before making any investment decisions.

‍

START TRADING TODAY

‍

Ready to get started?

Start trading with the full package, from state of the art platform to free tool and favorable transaction fees.

JOIN US NOW

All investments involve risks, including the possible loss of capital

©️ MEXEM AFRICA (PTY) LTD (MEXEM AFRICA) is an authorized financial services provider (FSP 48325). All trades on the MEXEM AFRICA platform are subject to the legal terms and conditions to which you agree to be bound.

The MEXEM AFRICA platform enables users to invest in securities. MEXEM AFRICA acts as an agent for the issuance of whole shares, where the investor is the registered owner of those shares, entitled to dividends, participation in corporate actions, and all the economic benefits and risks associated with share ownership.

The availability of any share on the MEXEM AFRICA platform is based on various factors but is not an indication of value and does not mean that any share is an appropriate investment for you. Images are for illustrative purposes only and past performance is not necessarily an indication of future performance.
‍
The availability of any share on the browse shares page does not necessarily indicate any contractual relationship between MEXEM AFRICA and the listed company or the payment of fees for services. Brand logos are owned by the respective companies and not by MEXEM AFRICA. The use of a company’s brand logo does not represent an endorsement of MEXEM AFRICA by the company, nor an endorsement of the company by MEXEM AFRICA, nor does it necessarily imply any contractual relationship. Further investment disclosures are available on the MEXEM AFRICA website.

Read our Forms & Disclosures.

‍

Pfizer seeks to raise $31 billion for Seagen acquisition

‍Company invests billions to counter $17 billion revenue shortfall by 2030

Ready to get started?

‍
Company invests billions to counter $17 billion revenue shortfall by 2030